| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/17/2001 | WO2001034169A1 Use of an extract from plantago lanceolata |
| 05/17/2001 | WO2001034165A1 Therapeutic compositions and methods of use thereof |
| 05/17/2001 | WO2001034162A1 Anti-hiv compositions |
| 05/17/2001 | WO2001034161A1 A method of treating substance addiction |
| 05/17/2001 | WO2001034160A1 Protease inhibitors |
| 05/17/2001 | WO2001034159A1 Protease inhibitors |
| 05/17/2001 | WO2001034158A1 Protease inhibitors |
| 05/17/2001 | WO2001034157A1 Protease inhibitors |
| 05/17/2001 | WO2001034156A1 Protease inhibitors |
| 05/17/2001 | WO2001034155A1 Protease inhibitors |
| 05/17/2001 | WO2001034154A1 Protease inhibitors |
| 05/17/2001 | WO2001034153A1 Protease inhibitors |
| 05/17/2001 | WO2001034152A1 Nasal drops containing fused pyridazine derivatives |
| 05/17/2001 | WO2001034151A1 Novel topoisomerase poisons for the treatment of proliferative disorders |
| 05/17/2001 | WO2001034150A1 Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents |
| 05/17/2001 | WO2001034149A1 Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 05/17/2001 | WO2001034148A1 Solid preparations for oral use |
| 05/17/2001 | WO2001034147A1 Oral solid preparation |
| 05/17/2001 | WO2001034145A1 Treating cancer by increasing intracellular malonyl coa levels |
| 05/17/2001 | WO2001034144A1 Lipoxin a4 and its analogs for the treatment of dry eye |
| 05/17/2001 | WO2001034143A1 Preventive or therapeutic agents for inflammatory diseases of intestine |
| 05/17/2001 | WO2001034142A1 A method of treating and lightening hyperpigmentation in black skin with a retinoid |
| 05/17/2001 | WO2001034141A1 Il-8 receptor antagonists |
| 05/17/2001 | WO2001034140A1 Pharmaceutical formulation |
| 05/17/2001 | WO2001034139A1 Pharmaceutical formulation containing tolterodine and its use |
| 05/17/2001 | WO2001034138A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 05/17/2001 | WO2001034137A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034136A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 05/17/2001 | WO2001034135A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034132A2 Use of an aldosterone antagonist for treating restenosis |
| 05/17/2001 | WO2001034131A2 Combination chemotherapy |
| 05/17/2001 | WO2001034130A1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 05/17/2001 | WO2001034129A2 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 05/17/2001 | WO2001034128A2 Admixture for intravenous administration of linezolid and other antibacterial agents |
| 05/17/2001 | WO2001034127A1 Prevention of plaque rupture by acat inhibitors |
| 05/17/2001 | WO2001034126A2 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| 05/17/2001 | WO2001034125A2 Therapeutic use and formulation of (-)-tramadol |
| 05/17/2001 | WO2001034124A2 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system |
| 05/17/2001 | WO2001034120A1 Apparatus and method for preparing microparticles using in-line solvent extraction |
| 05/17/2001 | WO2001034119A2 Inhibitors of crystallization in a solid dispersion |
| 05/17/2001 | WO2001034118A2 Solid dispersion pharmaceutical formulations |
| 05/17/2001 | WO2001034117A1 A method for chemoprevention of prostate cancer |
| 05/17/2001 | WO2001034116A2 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias |
| 05/17/2001 | WO2001034114A1 Liquid heparin formulation |
| 05/17/2001 | WO2001034113A2 Apparatus and method for preparing microparticles |
| 05/17/2001 | WO2001034099A1 Soy depigmenting and skin care compositions |
| 05/17/2001 | WO2001034094A2 Novel compounds to treat diabetes and associated conditions |
| 05/17/2001 | WO2001034093A2 Potentiation of prodrug efficacy |
| 05/17/2001 | WO2001034088A2 Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders |
| 05/17/2001 | WO2001033975A1 Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions |
| 05/17/2001 | WO2001033966A2 Active ingredient combination having insecticidal and acaricidal characteristics |
| 05/17/2001 | WO2001033942A1 Method for producing metabolites from plants cultivated in soil-less medium |
| 05/17/2001 | WO2001026646A8 NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
| 05/17/2001 | WO2001024796A8 1,2,4-triazole derivatives, composition, process of making and methods of use |
| 05/17/2001 | WO2001022955A3 Novel combination of loteprednol and antihistamines |
| 05/17/2001 | WO2001019356A3 High lipid diet |
| 05/17/2001 | WO2001014360A3 Benzopyrans and benzothiopyrans as rar selective retinoid agonists |
| 05/17/2001 | WO2001014358A3 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 05/17/2001 | WO2001009116A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/17/2001 | WO2001007602A3 Oligonucleotides for inhibiting the expression of human eg5 |
| 05/17/2001 | WO2001007408A3 Novel method for preparing benzoperhydroisoindole compounds |
| 05/17/2001 | WO2001005427B1 Psca: prostate stem cell antigen and uses thereof |
| 05/17/2001 | WO2001005425A3 Combined preparations comprising daunorubicin derivatives and her2 antibodies |
| 05/17/2001 | WO2001005390A3 Method for treating chronic pain using mek inhibitors |
| 05/17/2001 | WO2001002593A3 Control of gene expression in eukaryotic cells |
| 05/17/2001 | WO2001001973A8 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/17/2001 | WO2001001932A3 Oligosaccharide aldonic acids and their topical use |
| 05/17/2001 | WO2000077166A3 Gene expression modulated in gastrointestinal inflammation |
| 05/17/2001 | WO2000076499A3 Neuroprotective and retinoprotective ophthalmologic medicines |
| 05/17/2001 | WO2000076457A3 Il-8 receptor antagonists |
| 05/17/2001 | WO2000074665A3 New use of macrolide compounds for inducing chondrogenic differentiation |
| 05/17/2001 | WO2000072837A3 Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives |
| 05/17/2001 | WO2000071108A3 Methods for treatment of asthma using s-oxybutynin |
| 05/17/2001 | WO2000062742A3 Methods for regulating the condition of mammalian keratinous tissue |
| 05/17/2001 | WO2000057836A3 Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of cd44 membrane receptors of skin cells |
| 05/17/2001 | WO2000041484A3 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 05/17/2001 | WO2000040230A3 Hormone replacement for breast cancer patients |
| 05/17/2001 | WO2000030671A9 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 05/17/2001 | WO2000024755A9 Ovary-specific genes and proteins |
| 05/17/2001 | WO2000002569A3 Compositions for the treatment of atherosclerosis and related conditions |
| 05/17/2001 | WO1999044620A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/17/2001 | WO1999040883A3 Compositions and methods for the treatment of cystic fibrosis |
| 05/17/2001 | US20010001307 And mineral; for suppressing or ameliorating a symptom accompanying diminished homeostasis; having a reduced peculiar metal taste |
| 05/17/2001 | US20010001306 Method for inhibiting bone resorption |
| 05/17/2001 | DE19954934A1 Verfahren zur Solubilisierung von optischen Markern Process for the solubilization of optical markers |
| 05/17/2001 | DE19954816A1 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases |
| 05/17/2001 | DE19954707A1 Imidazolverbindungen als Phosphodiesterase VII-Hemmer Imidazole compounds as phosphodiesterase VII inhibitor |
| 05/17/2001 | DE19954569A1 Pharmakologisch aktive Tetrahydrothiopyran-4-ol-Derivate, Verfahren zu ihrer Herstellung und Verwendung Pharmacologically active tetrahydrothiopyran-4-ol derivatives, processes for their preparation and use |
| 05/17/2001 | DE19954516A1 Epinastin-haltige Lösungen Epinastine-containing solutions |
| 05/17/2001 | DE19954394A1 Verwendung von Polysiloxanen mit quartären Aminogruppen als Formulierungshilfe und Mittel enthalten dieselben Use of polysiloxanes with quaternary amino groups as a formulation aid and medium containing the same |
| 05/17/2001 | DE19954105A1 Treatment of estrogen deficiency-associated conditions, e.g. menopausal syndrome, osteoporosis, infertility or prostatic hypertrophy, using new or known gonatrienes having tissue-selective estrogenic activity |
| 05/17/2001 | DE19953899A1 Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Carboxamide-substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 05/17/2001 | DE19953625A1 Verwendung von 5HT-1A Serotonin Rezeptor Agonisten zur Behandlung von genetischen oder funktionellen Atemrhythmusstörungen Use of 5-HT 1A serotonin receptor agonist for the treatment of genetic or functional respiratory arrhythmia |
| 05/17/2001 | DE19952983A1 Verfahren zum Transfer von molekularen Substanzen mit prokaryontischen nukleinsäurebindenden Proteinen A method for the transfer of molecular substances with prokaryotic nucleic acid binding proteins |
| 05/17/2001 | CA2854796A1 Hydromorphinone and hydrocodeinone compositions and methods for their synthesis |
| 05/17/2001 | CA2391448A1 Use of vasoactive intestinal peptides and kits therefor |
| 05/17/2001 | CA2391416A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | CA2391369A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 05/17/2001 | CA2391299A1 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 05/17/2001 | CA2391278A1 Therapeutic compositions and methods of use thereof |